Management Team


barbaraheadshot2.jpg

Barbara S. Fox, PhD (CEO) 

Barbara Fox is the founding CEO of Tilos Therapeutics. She has previously served as Entrepreneur-in-Residence at Partners Innovation Fund, founder and CEO of Avaxia Biologics, founder and CSO of Recovery Pharmaceuticals, VP Discovery and Immunology at ImmuLogic Pharmaceutical Corp., and Associate Professor of Rheumatology at the U. Maryland School of Medicine. Barbara received her AB in chemistry from Bryn Mawr, her PhD in chemistry from MIT and trained as a post-doc in cellular immunology at the NIH. She was an EY Entrepreneur of The Year™ 2014 Award finalist in New England.


JohnHeadshot.jpg

John Edwards (Executive Chair)

John Edwards has over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals, involving over 10 FDA approved biologics at a series of successful biotechnology companies. Most recently he helped lead Adnexus from a start-up to the $450M acquisition by BMS within 4 years, where he then continued with the company for next 3 years serving as President. Earlier, John was VP Sales, Marketing, and Medical Affairs at Transkaryotic Therapies and had a 15-year tenure with Genetics Institute/Wyeth, where he held senior-level positions in R&D, manufacturing, and commercial operations. Currently, John also serves as executive chairman of F-star.  He started his career in R&D at Genzyme (pre-IPO). John received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the U. Massachusetts at Amherst. 


Jessie_Headshot.jpg

Jessie English, PhD (CSO) 

Jessie English is Chief Scientific Officer of Tilos Therapeutics. Jessie has many years of experience in immuno-oncology, serving most recently as VP and Head of Discovery Research ImmunoOncology Translational Innovation Platform at EMD Serono / Merck KGaA.  Jessie’s earlier positions included Head of Research at the Belfer Center for Applied Cancer Science at the Dana-Farber, VP of Kinase Biology at ArQule, oncology site lead for external discovery at Merck, and head of Pfizer's Kinase Center of Emphasis.  She began her career in industry at Schering-Plough in Oncology Discovery. Jessie earned her PhD in neurobiology from UNC and trained as a post-doc at UT Southwestern Medical Center.